Saturday 17 October 2026 Export MDXG’s income statement to Excel — free account

MiMedx Group, Inc

MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue fell 34.7%, EPS fell 242.9%, free cash flow fell 174.8% and total debt fell 6.80%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

4.43 0.25 −5.34%

Follow MDXG

Alert me

Market cap: $682.2M
P/E: 111×
Fwd P/E: −31.2×
Dividend yield: —
F-score: 5/9
Altman Z: 9.38
Beneish M: −2.68
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

MiMedx Group, Inc (MDXG) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, MiMedx Group, Inc (MDXG) trades at a P/E ratio of 111×. Over the past ten years it has ranged from 0.0× (December 2023) to 4,042× (March 2017); the current reading is higher than 90% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/MDXG/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="MiMedx Group, Inc P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/MDXG/metrics/pe-ratio">MiMedx Group, Inc (MDXG) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	20.5×	(40.29%)
FY2024	34.4×	74.62%
FY2023	19.7×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	21.3×	(99.42%)
FY2016	3,650×	10,807.15%

Period	P/E ratio	Change
Jun 2026	96.3×	411.71%
Mar 2026	18.8×	(8.31%)
Dec 2025	20.5×	(17.70%)
Sep 2025	24.9×	(10.24%)
42 more quarters	Free account

Against its own ten years

Low 0.0× High 4,042×

Ten-year median 11.7×

Current reading's percentile 85

Company	P/E ratio
GYRE Gyre Therapeutics, Inc. compare	n/m
DSGN Design Therapeutics, Inc. compare	n/m
ANNX Annexon, Inc. compare	n/m
CADL Candel Therapeutics, Inc. compare	n/m
OABI OmniAb, Inc. compare	n/m
AURA Aura Biosciences, Inc. compare	n/m
PHAR Pharming Group N.V. Sponsored ADR compare	62.4×
MDXG MiMedx Group, Inc	111×
ANL Adlai Nortye Ltd. Sponsored ADR compare	—
Biotechnology industry median	8.5×
Healthcare sector median	23.0×
Market median	18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

MiMedx Group, Inc (MDXG) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on MDXG

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on MDXG

Stockrow Weekly